FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981420512> ?p ?o ?g. }

• W2981420512 endingPage "745" @default.
• W2981420512 startingPage "738" @default.
• W2981420512 abstract "Abstract Purpose: Tumor-infiltrating lymphocytes (TIL) are associated with benefit to trastuzumab and chemotherapy in patients with early-stage HER2+ breast cancer. The predictive value of TILs, TIL subsets, and other immune cells in patients receiving chemotherapy-sparing lapatinib plus trastuzumab treatment is unclear. Experimental Design: Hematoxylin and eosin–stained slides (n = 59) were used to score stromal (s-)TILs from pretreatment biopsies of patients enrolled in the neoadjuvant TBCRC006 trial of 12-week lapatinib plus trastuzumab therapy (plus endocrine therapy for ER+ tumors). A 60% threshold was used to define lymphocyte-predominant breast cancer (LPBC). Multiplexed immunofluorescence (m-IF) staining (CD4, CD8, CD20, CD68, and FoxP3) and multispectral imaging were performed to characterize immune infiltrates in single formalin-fixed paraffin-embedded slides (n = 33). Results: The pathologic complete response (pCR) rate was numerically higher in patients with LPBC compared with patients with non-LPBC (50% vs. 19%, P = 0.057). Unsupervised hierarchical clustering of the five immune markers identified two patient clusters with different responses to lapatinib plus trastuzumab treatment (pCR = 7% vs. 50%, for cluster 1 vs. 2 respectively; P = 0.01). In multivariable analysis, cluster 2, characterized by high CD4+, CD8+, CD20+ s-TILs, and high CD20+ intratumoral TILs, was independently associated with a higher pCR rate (P = 0.03). Analysis of single immune subpopulations revealed a significant association of pCR with higher baseline infiltration by s-CD4, intratumoral (i-) CD4, and i-CD20+ TILs. Conclusions: LPBC was marginally associated with higher pCR rate than non-LPBC in patients with lapatinib plus trastuzumab treated HER2+ breast cancer. Quantitative assessment of the immune infiltrate by m-IF is feasible and may help correlate individual immune cell subpopulations and immune cell profiles with treatment response." @default.
• W2981420512 created "2019-11-01" @default.
• W2981420512 creator A5002405692 @default.
• W2981420512 creator A5009790407 @default.
• W2981420512 creator A5015435030 @default.
• W2981420512 creator A5018592715 @default.
• W2981420512 creator A5023898240 @default.
• W2981420512 creator A5026024346 @default.
• W2981420512 creator A5026237890 @default.
• W2981420512 creator A5027914471 @default.
• W2981420512 creator A5027985884 @default.
• W2981420512 creator A5029018985 @default.
• W2981420512 creator A5030115311 @default.
• W2981420512 creator A5035308541 @default.
• W2981420512 creator A5040020339 @default.
• W2981420512 creator A5040506127 @default.
• W2981420512 creator A5044880752 @default.
• W2981420512 creator A5050694233 @default.
• W2981420512 creator A5069398684 @default.
• W2981420512 creator A5072850149 @default.
• W2981420512 creator A5073398031 @default.
• W2981420512 creator A5077235697 @default.
• W2981420512 creator A5080914070 @default.
• W2981420512 creator A5081259888 @default.
• W2981420512 creator A5082726917 @default.
• W2981420512 creator A5085142676 @default.
• W2981420512 creator A5089513581 @default.
• W2981420512 date "2020-02-01" @default.
• W2981420512 modified "2023-10-12" @default.
• W2981420512 title "Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy" @default.
• W2981420512 cites W1530219086 @default.
• W2981420512 cites W2006070721 @default.
• W2981420512 cites W2076669505 @default.
• W2981420512 cites W2088160256 @default.
• W2981420512 cites W2092772483 @default.
• W2981420512 cites W2098683355 @default.
• W2981420512 cites W2103452148 @default.
• W2981420512 cites W2104453868 @default.
• W2981420512 cites W2107380545 @default.
• W2981420512 cites W2107894271 @default.
• W2981420512 cites W2112648444 @default.
• W2981420512 cites W2120431466 @default.
• W2981420512 cites W2125885282 @default.
• W2981420512 cites W2130900820 @default.
• W2981420512 cites W2147299492 @default.
• W2981420512 cites W2148811436 @default.
• W2981420512 cites W2149668671 @default.
• W2981420512 cites W2152811375 @default.
• W2981420512 cites W2157058802 @default.
• W2981420512 cites W2162982444 @default.
• W2981420512 cites W2163871197 @default.
• W2981420512 cites W2178732328 @default.
• W2981420512 cites W2221588520 @default.
• W2981420512 cites W2313168486 @default.
• W2981420512 cites W2407664560 @default.
• W2981420512 cites W2506902454 @default.
• W2981420512 cites W2520500352 @default.
• W2981420512 cites W2559561655 @default.
• W2981420512 cites W2559858344 @default.
• W2981420512 cites W2562493667 @default.
• W2981420512 cites W2587365770 @default.
• W2981420512 cites W2591481727 @default.
• W2981420512 cites W2727635070 @default.
• W2981420512 cites W2764265362 @default.
• W2981420512 cites W2767814595 @default.
• W2981420512 cites W2803146319 @default.
• W2981420512 cites W2910609377 @default.
• W2981420512 cites W2930274452 @default.
• W2981420512 cites W2982414110 @default.
• W2981420512 cites W4234081105 @default.
• W2981420512 doi "https://doi.org/10.1158/1078-0432.ccr-19-1402" @default.
• W2981420512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7002194" @default.
• W2981420512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31653641" @default.
• W2981420512 hasPublicationYear "2020" @default.
• W2981420512 type Work @default.
• W2981420512 sameAs 2981420512 @default.
• W2981420512 citedByCount "27" @default.
• W2981420512 countsByYear W29814205122020 @default.
• W2981420512 countsByYear W29814205122021 @default.
• W2981420512 countsByYear W29814205122022 @default.
• W2981420512 countsByYear W29814205122023 @default.
• W2981420512 crossrefType "journal-article" @default.
• W2981420512 hasAuthorship W2981420512A5002405692 @default.
• W2981420512 hasAuthorship W2981420512A5009790407 @default.
• W2981420512 hasAuthorship W2981420512A5015435030 @default.
• W2981420512 hasAuthorship W2981420512A5018592715 @default.
• W2981420512 hasAuthorship W2981420512A5023898240 @default.
• W2981420512 hasAuthorship W2981420512A5026024346 @default.
• W2981420512 hasAuthorship W2981420512A5026237890 @default.
• W2981420512 hasAuthorship W2981420512A5027914471 @default.
• W2981420512 hasAuthorship W2981420512A5027985884 @default.
• W2981420512 hasAuthorship W2981420512A5029018985 @default.
• W2981420512 hasAuthorship W2981420512A5030115311 @default.
• W2981420512 hasAuthorship W2981420512A5035308541 @default.
• W2981420512 hasAuthorship W2981420512A5040020339 @default.
• W2981420512 hasAuthorship W2981420512A5040506127 @default.
• W2981420512 hasAuthorship W2981420512A5044880752 @default.
• W2981420512 hasAuthorship W2981420512A5050694233 @default.

• next